PGI Drug Discovery

PsychoGenics is a leading phenomics-based drug discovery company and contract research organization (CRO) specializing in central nervous system (CNS) disorders. The company utilizes its proprietary high-throughput behavioral testing platforms, such as SmartCube, NeuroCube, and PhenoCube, which combine computer vision and artificial intelligence to identify next-generation neuropsychiatric treatments. PsychoGenics has successfully partnered with major pharmaceutical companies to discover clinical-stage assets, most notably Ulotaront (SEP-363856), a first-in-class TAAR1 agonist for schizophrenia developed in collaboration with Sunovion. Beyond its service business, the company maintains an internal pipeline of small molecule programs targeting various psychiatric and neurological conditions.